HC Wainwright Reiterates Buy Rating for Pharming Group (NASDAQ:PHAR)

HC Wainwright restated their buy rating on shares of Pharming Group (NASDAQ:PHAR) in a research report report published on Thursday,Benzinga reports. The brokerage currently has a $37.00 price objective on the stock.

Several other research analysts also recently weighed in on the stock. Oppenheimer upped their price objective on shares of Pharming Group from $30.00 to $39.00 and gave the stock an “outperform” rating in a report on Friday, March 14th. Jefferies Financial Group started coverage on shares of Pharming Group in a report on Monday, December 9th. They set a “buy” rating and a $14.00 price objective on the stock.

Pharming Group Stock Up 0.1 %

Shares of NASDAQ PHAR opened at $8.81 on Thursday. The firm has a market cap of $599.29 million, a PE ratio of -33.88 and a beta of -0.10. Pharming Group has a 12-month low of $6.65 and a 12-month high of $11.30. The company’s fifty day simple moving average is $8.91 and its 200 day simple moving average is $8.61. The company has a quick ratio of 2.76, a current ratio of 3.53 and a debt-to-equity ratio of 0.41.

Pharming Group (NASDAQ:PHAR) last released its quarterly earnings data on Thursday, March 13th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.02). Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. The business had revenue of $92.70 million for the quarter, compared to analyst estimates of $76.67 million. As a group, sell-side analysts forecast that Pharming Group will post -0.2 earnings per share for the current fiscal year.

Institutional Trading of Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its position in Pharming Group (NASDAQ:PHAR) by 16.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 47,997 shares of the company’s stock after purchasing an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned about 0.07% of Pharming Group worth $483,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 0.03% of the company’s stock.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.